EPEN-06. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. (3rd June 2022)

• Record Type: Journal Article
• Authors: Bockmayr, Michael; Harnisch, Kim; Pohl, Lara; Schweizer, Leonille; Mohme, Theresa; Körner, Meik; Alawi, Malik; Suwala, Abigail; Dorostkar, Mario; Monoranu, Camelia; Hasselblatt, Martin; Wefers, Annika; Capper, David; Hench, Jürgen; Frank, Stephan; Richardson, Timothy; Tran, Ivy; Liu, Elisa; Snuderl, Matija; Engertsberger, Lara; Benesch, Martin; von Deimling, Andreas; Obrecht, Denise; Mynarek, Martin; Rutkowski, Stefan; Glatzel, Markus; Neumann, Julia; Schüller, Ulrich
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 1
• Page Start: i39
• Page End: i39
• Publication Date: 2022-06-03
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac079.143
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Myxopapillary ependymoma (MPE) is a heterogeneous disease regarding histopathology and outcome. The underlying molecular biology is poorly understood, and markers that reliably predict the patients' clinical course are unknown. We assembled a cohort of 185 tumors classified as MPE based on DNA methylation from pediatric, adolescent, and adult patients. Methylation patterns, copy number profiles, and MGMT promoter methylation were analyzed for all tumors, 106 tumors were evaluated histomorphologically, and RNA sequencing was performed for 37 cases. Based on methylation profiling, we defined two subtypes MPE-A and MPEB, and explored associations with epidemiological, clinical, pathological, and molecular characteristics of these tumors. Tumors in the methylation class MPE were histologically diagnosed as WHO grade I (59%), WHO grade II (37%), or WHO grade III tumors (4%). 75/77 analyzed tumors expressed HOXB13, which is a diagnostic feature not detected in other spinal ependymal tumors. Based on DNA methylation, our series split into two subtypes. MPE-A occurred in younger patients (median age 27 vs. 45 years, p=7.3e-05). They were enriched with WHO grade I tumors and associated with papillary morphology and MGMT promoter hypermethylation (all p<0.001). MPE-B included most tumors initially diagnosed as WHO grade II and cases with tanycytic morphology. Copy number alterations were more common in MPE-A. RNA sequencing revealed an enrichment for extracellular matrix and immune system-related signatures in MPE-A. 15/30 MPE-A could not be totally resected compared to 1/58 MPE-B (p=6.3e-08), and progression-free survival was significantly better for MPE-B (p=3.4e-06, 10-year relapse rate 33% vs. 85%). We unraveled the morphological and clinical heterogeneity of MPE by identifying two molecularly distinct subtypes. These subtypes significantly differed in progression-free survival and will likely need different protocols for surveillance and treatment.